Table 2.
Treatment | Time (min) | Nitrotyrosine (μg/ml) | LDF (AU) | So2 (%) | Aix (%) |
---|---|---|---|---|---|
HI | 30 | 0.25 ± 0.15 | −2.2 ± 2.5 | −2.1 ± 1.1 | −3.9 ± 1.4 |
LI | 30 | 0.09 ± 0.07 | −5.0 ± 4.5 | −2.4 ± 1.6 | −1.1 ± 1.6 |
VJ | 30 | −0.26 ± 0.17* | 4.1 ± 2.4*† | 2.5 ± 2.3*† | −3.0 ± 2.2 |
HI | 60 | 0.22 ± 0.17 | 1.2 ± 3.1 | −1.9 ± 1.6 | −5.0 ± 1.1 |
LI | 60 | −0.05 ± 0.16 | 1.9 ± 7.6 | −2.5 ± 1.9 | −3.5 ± 1.4 |
VJ | 60 | −0.03 ± 0.20 | 7.1 ± 5.7 | 2.7 ± 2.4*† | −3.5 ± 1.8 |
HI | 120 | 0.22 ± 0.23 | 5.4 ± 2.2 | 0.4 ± 1.2 | −2.6 ± 1.8 |
LI | 120 | 0.16 ± 0.18 | 0.5 ± 3.5 | 1.4 ± 1.7 | −0.3 ± 1.7 |
VJ | 120 | 0.00 ± 0.22 | 3.1 ± 5.0 | 0.6 ± 2.4 | −2.8 ± 1.5 |
HI | 180 | 0.06 ± −0.24 | 4.8 ± 2.9 | 0.8 ± 1.5 | −0.9 ± 1.3 |
LI | 180 | −0.06 ± 0.22 | −1.2 ± 7.3 | −0.6 ± 2.1 | 2.6 ± 1.7 |
VJ | 180 | −0.16 ± 0.17 | 4.5 ± 7.6 | −0.8 ± 2.2 | 1.6 ± 2.4 |
HI | 240 | 0.16 ± 0.24 | 1.1 ± 3.3 | 1.2 ± 1.2 | −0.4 ± 1.2 |
LI | 240 | −0.07 ± 0.23 | 1.4 ± 6.7 | −1.2 ± 1.4 | 1.1 ± 1.2 |
VJ | 240 | −0.26 ± 0.18 | 9.1 ± 9.4 | −0.8 ± 1.8 | 0.8 ± 2.2 |
Data are means ± SEM.
*P < 0.05 vs. human regular insulin.
†P < 0.05 vs. insulin lispro. AU, arbitrary units; HI, human insulin; LI, insulin lispro; VJ, VIAject.